

Mary R Cahill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3187774/publications.pdf>

Version: 2024-02-01

45
papers

704
citations

567281

15
h-index

552781

26
g-index

45
all docs

45
docs citations

45
times ranked

3432
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel 33â€Gene targeted resequencing panel provides accurate, clinicalâ€grade diagnosis and improves patient management for rare inherited anaemias. <i>British Journal of Haematology</i> , 2016, 175, 318-330.	2.5	72
2	Duration of increased bleeding tendency after cessation of aspirin therapy. <i>Journal of the American College of Surgeons</i> , 2005, 200, 564-573.	0.5	68
3	Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, <i>in Vitro</i> Mechanistic Studies, and <i>ex Vivo</i> Patient Derived Therapeutic Efficacy. <i>Molecular Pharmaceutics</i> , 2017, 14, 940-952.	4.6	56
4	A multiâ€centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. <i>British Journal of Haematology</i> , 2013, 163, 118-122.	2.5	50
5	Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation. <i>Experimental Hematology</i> , 2015, 43, 781-793.e2.	0.4	49
6	Induction of autophagy by Imatinib sequesters Bcrâ€Abl in autophagosomes and downâ€regulates Bcrâ€Abl protein. <i>American Journal of Hematology</i> , 2013, 88, 455-462.	4.1	45
7	The effectiveness of interventions to improve laboratory requesting patterns among primary care physicians: a systematic review. <i>Implementation Science</i> , 2015, 10, 167.	6.9	45
8	Regulation of Trib2 by an E2F1-C/EBPÎ± feedback loop in AML cell proliferation. <i>Blood</i> , 2014, 123, 2389-2400.	1.4	44
9	Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia. <i>Biotechnology Advances</i> , 2014, 32, 1396-1409.	11.7	38
10	Retinoid receptor signaling and autophagy in acute promyelocytic leukemia. <i>Experimental Cell Research</i> , 2014, 324, 1-12.	2.6	37
11	Adhesion Molecules in Clinical Medicine. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 1998, 35, 415-459.	6.1	23
12	Writing to patients: a randomised controlled trial. <i>Clinical Medicine</i> , 2006, 6, 178-182.	1.9	22
13	Allâ€trans</i> retinoic acid (ATRA)â€induced <i>TFEB</i> expression is required for myeloid differentiation in acute promyelocytic leukemia (APL). <i>European Journal of Haematology</i> , 2020, 104, 236-250.	2.2	21
14	The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia. <i>Journal of Controlled Release</i> , 2018, 286, 154-166.	9.9	19
15	Haematinic Deficiency and Macrocytosis in Middle-Aged and Older Adults. <i>PLoS ONE</i> , 2013, 8, e77743.	2.5	18
16	RNA interference for multiple myeloma therapy: targeting signal transduction pathways. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 107-121.	3.4	16
17	Inhibition of UBE2L6 attenuates ISGylation and impedes ATRAâ€induced differentiation of leukemic cells. <i>Molecular Oncology</i> , 2020, 14, 1297-1309.	4.6	15
18	Detection of Aspirin Resistance by PFA-100: Prevalence and Aspirin Compliance in Patients with Chronic Stable Angina. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 420-425.	2.7	13

#	ARTICLE	IF	CITATIONS
19	Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 2021, 192, 322-332.	2.5	9
20	Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG] Tj ETQc0 0 0 rgBT /Overlock 10 abbreviated frontline therapy with FCR in non-del(17p) CLL. <i>Leukemia and Lymphoma</i> , 2018, 59, 1338-1347.	1.3	7
21	The Importance of Alpha-Actinin Proteins in Platelet Formation and Function, and Their Causative Role in Congenital Macrothrombocytopenia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9363.	4.1	5
22	The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine.. <i>Blood</i> , 2009, 114, 2087-2087.	1.4	5
23	Theranostic drug test incorporating the boneâ€marrow microenvironment can predict the clinical response of acute myeloid leukaemia to chemotherapy. <i>British Journal of Haematology</i> , 2020, 189, e254-e258.	2.5	4
24	Smoking as an independent risk factor for macrocytosis in middleâ€aged adults: A populationâ€based observational study. <i>American Journal of Hematology</i> , 2015, 90, E196-7.	4.1	3
25	Physician and practice characteristics associated with immunoglobulin test ordering. <i>Family Practice</i> , 2018, 35, 41-46.	1.9	3
26	Cigarette Smoking Is An Under Recognised Cause Of Macrocytosis. <i>Blood</i> , 2013, 122, 4660-4660.	1.4	3
27	Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, 562-573.	4.1	3
28	All-Trans-Retinoic Acid Combined With Valproic Acid Can Promote Differentiation in Myeloid Leukemia Cells by an Autophagy Dependent Mechanism. <i>Frontiers in Oncology</i> , 2022, 12, 848517.	2.8	3
29	Educational intervention to optimise serum immunoglobulin test use in Irish primary care: an interrupted time series with segmented regression analysis. <i>British Journal of General Practice</i> , 2020, 70, e146-e154.	1.4	2
30	Can absolute basophilia distinguish e1a2 BCR-ABL1 chronic myeloid leukemia from chronic myelomonocytic leukemia?. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 87, 102521.	1.4	2
31	Autophagy As a Target for Differentiation Therapy in Acute Myeloid Leukemia.. <i>Blood</i> , 2012, 120, 2464-2464.	1.4	2
32	Polycythemia vera emerging eighteen years after acute myeloid leukemia diagnosis. <i>Blood Research</i> , 2021, 56, 121-123.	1.3	1
33	Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight. <i>Blood</i> , 2016, 128, 3237-3237.	1.4	1
34	Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCRâ€ABL chronic myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, e176-e177.	0.8	0
35	CALR mutation profile in Irish patients with myeloproliferative neoplasms. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 112-115.	0.9	0
36	Platelet hyperactivation and hyporesponsiveness at diagnosis in multiple myeloma persists during treatment initiation. <i>Thrombosis Research</i> , 2021, 203, 186-189.	1.7	0

#	ARTICLE	IF	CITATIONS
37	Phase 1 Clinical Trial of Prion-Filtered Red Cell Concentrates (pfRCC) in Patients Requiring Allogeneic Blood Transfusion.. Blood, 2008, 112, 994-994.	1.4	0
38	Irish Hospitals Meet Proposed International Guidelines For Non-Hodgkin Lymphoma Management, But Areas For Improvement Remain. Blood, 2013, 122, 5591-5591.	1.4	0
39	Macrocytosis: A Metabolic Marker?. Blood, 2013, 122, 4663-4663.	1.4	0
40	Radiation Exposure From Diagnostic Imaging in Patients with Lymphoma - The Cost Of The Cure?. Blood, 2013, 122, 557-557.	1.4	0
41	Elucidation and Therapeutic Targeting Of The Molecular Mechanism Of TRIB2-Mediated Acute Myeloid Leukaemia. Blood, 2013, 122, 3799-3799.	1.4	0
42	ATRA-Induced Activation of the Autophagy Regulator Tfeb Regulates Myeloid Differentiation in Acute Promyelocytic Leukemia. Blood, 2014, 124, 1057-1057.	1.4	0
43	Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study. Blood, 2018, 132, 3242-3242.	1.4	0
44	Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia. Blood, 2021, 138, 1218-1218.	1.4	0
45	Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level. British Journal of Haematology, 2022, , .	2.5	0